Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun;18(3):48.
doi: 10.1007/s10544-016-0072-0.

Microfluidic manufacture of rt-PA -loaded echogenic liposomes

Affiliations

Microfluidic manufacture of rt-PA -loaded echogenic liposomes

Madhuvanthi A Kandadai et al. Biomed Microdevices. 2016 Jun.

Abstract

Echogenic liposomes (ELIP), loaded with recombinant tissue-type plasminogen activator (rt-PA) and microbubbles that act as cavitation nuclei, are under development for ultrasound-mediated thrombolysis. Conventional manufacturing techniques produce a polydisperse rt-PA-loaded ELIP population with only a small percentage of particles containing microbubbles. Further, a polydisperse population of rt-PA-loaded ELIP has a broadband frequency response with complex bubble dynamics when exposed to pulsed ultrasound. In this work, a microfluidic flow-focusing device was used to generate monodisperse rt-PA-loaded ELIP (μtELIP) loaded with a perfluorocarbon gas. The rt-PA associated with the μtELIP was encapsulated within the lipid shell as well as intercalated within the lipid shell. The μtELIP had a mean diameter of 5 μm, a resonance frequency of 2.2 MHz, and were found to be stable for at least 30 min in 0.5 % bovine serum albumin. Additionally, 35 % of μtELIP particles were estimated to contain microbubbles, an order of magnitude higher than that reported previously for batch-produced rt-PA-loaded ELIP. These findings emphasize the advantages offered by microfluidic techniques for improving the encapsulation efficiency of both rt-PA and perflurocarbon microbubbles within echogenic liposomes.

Keywords: Echogenic liposomes; Microfluidic flow-focusing; Recombinant tissue-type plasminogen activator; Stroke treatment; Ultrasound-mediated thrombolysis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
a Microfluidic device design showing the inner drug channels, outer lipid channels, orifice, and the outlet reservoir (b) zoomed-in view of the extrusion orifice, and c the microfluidic device
Fig. 2
Fig. 2
Microbubble formation downstream of the orifice showing the effect of increasing flow rates on particle sizes. The flow rates in images (a–c) are 40, 50, and 63.5 µL/min respectively. Scale bar: 50 µm
Fig. 3
Fig. 3
Microscopic images of particles obtained using (a) a low lipid concentration (2 mg/mL), and b higher lipid concentration (10 mg/mL)
Fig. 4
Fig. 4
Multisizer measurements showing number-weighted (left) and volume-weighted (right) µtELIP size distributions at (a–b) 10 min, c–d 16 min, and e–f 32 min
Fig. 5
Fig. 5
Average US attenuation of µtELIP suspended in 0.5 % BSA at 22.5 ± 0.5 °C measured after 30 min (N = 3). Error bars represent standard deviations
Fig. 6
Fig. 6
Measured attenuation coefficients as a function of frequency (dashed lines) and theoretical fits (solid lines) based on the estimated shell parameters of the µtELIP. The gray band denotes the 95 % confidence interval for the fit
Fig. 7
Fig. 7
a µtELIP diluted in 0.9 % saline without cobalt chloride quenching demonstrating the presence of adsorbed rt-PA on the µtELIP exterior surface (b) Fluorescent staining of a µtELIP showing the lipid layer in red and the calcein associated with encapsulated rt-PA in green without cobalt chloride (c) and after addition of cobalt chloride to quench fluorescence from rt-PA on the exterior of the liposomes
Fig. 8
Fig. 8
The amount of rt-PA associated with the rt-PA and lipid mixture extruded through the microfluidic device (148.70 ± 30.80 µg/mL) compared with that associated with the µtELIP shell (64.30 ± 3.80 µg/mL)

Similar articles

Cited by

References

    1. Akers MJ, Defelippis MR. In: Pharmaceutical Formulation Development of Peptides and Proteins. Frokjaer S, Hovgaard L, editors. Philadelphia: Taylor and Francis; 2000. pp. 145–177.
    1. Alexandrov AV, Grotta JC. Neurology. 2002;59(6):862–867. - PubMed
    1. Alexandrov AV, Wojner AW, Grotta JC. J. Neuroimaging. 2004;14(2):108–112. - PubMed
    1. Angilè FE, Vargo KB, Sehgal CM, Hammer DA, Lee D. Langmuir. 2014;30(42):12610–12618. - PMC - PubMed
    1. Bader KB, Holland CK. Phys. Med. Biol. 2013;58(1):127–144. - PMC - PubMed

Publication types

LinkOut - more resources